Compounding pharmacies, which customize drugs for individual patients, say the FDA is overstepping its authority and jeopardizing patient access to compounded medications.
The pharmacies say the Food and Drug Administration has misinterpreted Congress’s intent when it enacted the Drug Quality and Security Act (DQSA) of 2013 by not allowing office-use compounding. Office-use compounding is when a pharmacist makes a drug without receiving a prescription and transfers it to a requesting physician to keep on hand for when it is needed by a patient.
The pharmacies also are concerned that the FDA has issued no rules for compounding but only guidance documents, which aren’t legally enforceable.
“Mass confusion has resulted from the usage of guidance documents, and the FDA is definitely circumventing the Administrative Procedure Act (APA) in our opinion,” Cynthia Blankenship, executive vice president of the International Academy of Compounding Pharmacists (IACP), told me. The APA governs how federal agencies propose and establish regulations.
IACP wants Congress to pass a bill (H.R. 2871) they say will fix these issues. Under the bill, if state law authorizes office-use compounding then it wouldn’t be considered a violation. It also requires the FDA to go through rulemaking under the APA, among other things. The bill was introduced by Rep. Morgan Griffith (R-Va.) in June.
However, it’s unclear whether the bill will advance. Griffith said in an Oct. 19 statement provided to Bloomberg Law, “We hope that it will move forward at some point, but we have to do some more ground-building before it will move forward.”
Meanwhile, the FDA says its oversight of compounding pharmacies is essential to ensuring patient safety and says allowing office-use compounding could lead to contaminated drug products. The FDA also says it is encouraging more compounding pharmacies to register with the agency as outsourcing facilities, which are permitted to provide compounded drugs for office use because they are subject to higher manufacturing standards.
The DQSA, which was enacted after a deadly outbreak of fungal meningitis from compounded drugs provided by a pharmacy in Massachusetts in 2012, distinguishes between compounders engaged in traditional compounding and those compounders making large volumes of compounded drugs without individual prescriptions. Compounders wanting to make larger amounts of drugs without individual prescriptions can voluntarily register with the FDA as outsourcing facilities and become subject to federal manufacturing oversight like brand-name and generic drug manufacturers.
Julie Dohm, senior science adviser for compounding in the FDA’s Center for Drug Evaluation and Research, told me no facility would register as an outsourcing facility and become subject to federal oversight and pay the required fees to the FDA if they could remain a 503A compounding pharmacy and do the same thing, which is distribute nonpatient specific drugs for office use. “We obviously recognize how important it is for the outsourcing facilities to be able to meet the need for nonpatient specific compounded drugs. That’s what they were created to do, that’s what they’re allowed to do,” she said.
Read my full article here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)